BiomX, Inc. (PHGE)
Stock Price Chart
Key Info
| Market Cap | 139.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -33.01M |
| Shares Out | 23.15M |
| EPS (ttm) | -4.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 26, 2020 |
| Last Price | $6.01 |
| Previous Close | $5.96 |
| Change ($) | 0.05 |
| Change (%) | 0.84% |
| Day's Open | 6.23 |
| Day's Range | 6.01 - 6.23 |
| Day's Volume | 5,218 |
| 52-Week Range | 4.52 - 11.50 |
More Stats
| Market Cap | 139.11M |
| Enterprise Value | 69.52M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 23.15M |
| Float | 17.08M |
| EPS (basic) | -4.05 |
| EPS (diluted) | -4.05 |
| FCF / Share | -1.33 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 20,727 |
| Short Ratio | 2.77 |
| Short % of Float | 0.12% |
| Beta | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.95 |
| Revenue | n/a |
| Operating Income | -34.18M |
| Net Income | -33.01M |
| Free Cash Flow | -30.64M |
| Net Cash | 69.59M |
| Net Cash / Share | 3.01 |
| Gross Margin | n/a |
| Operating Margin | n/a |
| Profit Margin | n/a |
| FCF Margin | n/a |
| ROA | -27.89% |
| ROE | -45.97% |
| ROIC | -119.20% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Operating Income | -22.21 | -12.50 | -6.71 | -1.77 |
| Net Income | -20.56 | -12.72 | -6.43 | -1.90 |
| Shares Outstanding | 5.62 | 2.00 | 1.97 | 1.96 |
| Earnings Per Share | -3.66 | -7.62 | -3.76 | -1.01 |
| Operating Cash Flow | -17.58 | -11.30 | -4.10 | -1.34 |
| Capital Expenditures | -1.31 | -0.14 | -0.85 | -0.10 |
| Free Cash Flow | -18.89 | -11.44 | -4.95 | -1.43 |
| Cash & Equivalents | 82.41 | 39.75 | 8.15 | - |
| Total Debt | 1.23 | - | - | - |
| Net Cash / Debt | 81.18 | 39.75 | 8.15 | - |
| Assets | 92.12 | 45.33 | 13.99 | - |
| Liabilities | 7.67 | 2.53 | 2.46 | - |
| Book Value | 84.46 | 42.80 | 11.53 | - |
Company Profile
Company Details
| Full Name | BiomX, Inc. |
| Country | Israel |
| Employees | 73 |
| CEO | Jonathan Eithan Solomon |
Stock Information
| Ticker Symbol | PHGE |
| Stock Exchange | NYSE American |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NYSEAMERICAN: PHGE |
Description
BiomX, a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.